Deciduous Therapeutics Investors
Developer of novel therapeutics designed for the treatment of age-related diseases. The company's novel molecules can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells, enabling healthcare providers to treat several classes of age-related Therapeutics 2025 : Valuation, ?
Investors
Estimated Revenue:
26.5 million
Headquarters:
San Francisco, United States, California
Employee Number:
1-10
Founded Date:
2019